Financial Outcomes of “Bagging” Oncology Drugs Among Privately Insured Patients With Cancer

por Shih, Ya-Chen Tina, Xu, Ying, Yao, James Ching
Publicado 2023

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market

por Shih, Ya-Chen Tina, Xu, Ying, Zhao, Hui, Schrag, Deborah, Yao, James
Publicado 2021

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

por Kulke, Matthew H, Bendell, Johanna, Kvols, Larry, Picus, Joel, Pommier, Rodney, Yao, James
Publicado 2011

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology

por Serpas, Victoria J., Raghav, Kanwal P., Halperin, Daniel M., Yao, James, Overman, Michael J.
Publicado 2018

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers

por Halperin, Daniel M, Phan, Alexandria T, Hoff, Ana O, Aaron, Marie, Yao, James C, Hoff, Paulo M
Publicado 2014

Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis

por Mehrvarz Sarshekeh, Amir, Advani, Shailesh, Halperin, Daniel M., Conrad, Claudius, Shen, Chan, Yao, James C., Dasari, Arvind
Publicado 2017

Population-Based Study of Islet Cell Carcinoma

por Yao, James C., Eisner, Milton P., Leary, Colleen, Dagohoy, Cecile, Phan, Alexandria, Rashid, Asif, Hassan, Manal, Evans, Douglas B.
Publicado 2007

Characteristics of Epstein-Barr virus-associated gastric cancer: A study of 235 cases at a comprehensive cancer center in U.S.A

por Truong, Camtu D, Feng, Wei, Li, Wei, Khoury, T, Li, Q, Alrawi, S, Yu, Yingyan, Xie, Keping, Yao, James, Tan, Dongfeng
Publicado 2009

Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors

por Pudakalakatti, Shivanand, Titus, Mark, Enriquez, José S., Ramachandran, Sumankalai, Zacharias, Niki M., Shureiqi, Imad, Liu, Yi, Yao, James C., Zuo, Xiangsheng, Bhattacharya, Pratip K.
Publicado 2022

Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-3 Trial

por Lombard-Bohas, Catherine, Yao, James C., Hobday, Timothy, Van Cutsem, Eric, Wolin, Edward M., Panneerselvam, Ashok, Stergiopoulos, Sotirios, Shah, Manisha H., Capdevila, Jaume, Pommier, Rodney
Publicado 2015

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

por Yao, James C, Chan, Jennifer A, Mita, Alain C, Kundu, Madan G, Hermosillo Reséndiz, Karina, Hu, Ke, Ravichandran, Shoba, Strosberg, Jonathan R, Wolin, Edward M
Publicado 2017

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis

por Strosberg, Jonathan R, Yao, James C, Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D, Ruszniewski, Philippe B, Van Cutsem, Eric, Öberg, Kjell, Pavel, Marianne E
Publicado 2015

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms

por Yao, James, Bergsland, Emily, Aggarwal, Rahul, Aparicio, Ana, Beltran, Himisha, Crabtree, Judy S, Hann, Christine L, Ibrahim, Toni, Byers, Lauren A, Sasano, Hironobu, Umejiego, John, Pavel, Marianne
Publicado 2022

Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

por Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
Publicado 2019

The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment

por Balanescu, Dinu Valentin, Donisan, Teodora, Lopez-Mattei, Juan, Hassan, Saamir, Kim, Peter, Dasari, Arvind, Halperin, Daniel, Yao, James, Kar, Biswajit, Gregoric, Igor, Balanescu, Serban Mihai, Iliescu, Cezar
Publicado 2019

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

por Kaseb, Ahmed Omar, Hassan, Manal, Lacin, Sahin, Abdel-Wahab, Reham, Amin, Hesham M., Shalaby, Ahmed, Wolff, Robert A., Yao, James, Rashid, Asif, Vennapusa, Bharathi, Feng, Janine, Ohtomo, Toshihiko
Publicado 2016

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4

por Buzzoni, Roberto, Carnaghi, Carlo, Strosberg, Jonathan, Fazio, Nicola, Singh, Simron, Herbst, Fabian, Ridolfi, Antonia, Pavel, Marianne E, Wolin, Edward M, Valle, Juan W, Oh, Do-Youn, Yao, James C, Pommier, Rodney
Publicado 2017

PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment

por Liu, Yi, Wei, Daoyan, Deguchi, Yasunori, Xu, Weiguo, Tian, Rui, Liu, Fuyao, Xu, Min, Mao, Fei, Li, Donghui, Chen, Weidong, Valentin, Lovie Ann, Deguchi, Eriko, Yao, James C., Shureiqi, Imad, Zuo, Xiangsheng
Publicado 2023

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

por Wang, Yudong, Janku, Filip, Piha-Paul, Sarina, Hess, Kenneth, Broaddus, Russell, Liu, Lidong, Shi, Naiyi, Overman, Michael, Kopetz, Scott, Subbiah, Vivek, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Fu, Siqing
Publicado 2020

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

por Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Gong, Jing, Wathoo, Chetna, Shaw, Kenna, Hess, Kenneth, Broaddus, Russell, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Meric-Bernstam, Funda, Fu, Siqing
Publicado 2017